our Premium Content: News alerts, weekly reports and conference planners

GENE:

NRAS (Neuroblastoma RAS viral oncogene homolog)

News alerts, weekly reports and conference planners

Fibrotic marrow limiting morphologic classification in MDS/MPN with SF3B1 mutation and thrombocytosis: diagnostic implications under the ICC 2022 framework. (PubMed, Virchows Arch)

After ruxolitinib therapy, he later developed leukocytosis and 2% circulating blasts. Repeat marrow demonstrated ≥ 15% ring sideroblasts. Retrospectively, the initial biopsy fulfills ICC 2022 criteria for MDS/MPN-SF3B1-T, highlighting the diagnostic value of genetics-integrated classification in fibrotic marrows.

2 days ago

Journal

NRAS (Neuroblastoma RAS viral oncogene homolog) • JAK2 (Janus kinase 2) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1)

SF3B1 mutation • NRAS G12

Jakafi (ruxolitinib)

Clinical actionability of molecular testing in advanced thyroid cancer: a real-world cohort study. (PubMed, Eur Thyroid J)

Molecular testing frequently revealed targetable alterations in patients with advanced TC, and matched therapies yielded meaningful clinical benefit. These findings underscore the value of precision medicine in TC and support broader implementation of molecular-guided treatment strategies.

2 days ago

Journal • Real-world evidence

BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • NTRK (Neurotrophic receptor tyrosine kinase)

Comparative efficacy of donor lymphocyte infusions in augmenting graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with myeloid malignancies. (PubMed, Acta Haematol)

DLI is an effective treatment strategy for post-transplant relapse of all myeloid malignancies, with specific genetic subtypes showing poorer outcomes and survival.

2 days ago

Journal

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • JAK2 (Janus kinase 2) • RUNX1 (RUNX Family Transcription Factor 1)

TP53 mutation • KRAS mutation • NRAS mutation

Exosomal circ_0097112 drives icotinib resistance through activating RAF/MAPK signaling in lung adenocarcinoma. (PubMed, Cell Signal)

This molecular event consequently activates downstream RAF/MAPK signaling, attenuating apoptosis while promoting cellular proliferation and drug resistance. Collectively, this study reveals the pivotal involvement of the circ_0097112/UPF1/NRAS axis in driving EGFR-TKI resistance in LUAD and offers a new theoretical basis for targeting circ_0097112 to reverse EGFR-TKI resistance.

3 days ago

Journal

NRAS (Neuroblastoma RAS viral oncogene homolog) • UPF1 (UPF1 RNA Helicase And ATPase)

Conmana (icotinib)

NF1 mutation may be associated with lung-tropic metastasis in cutaneous melanoma: a genomic analysis of 520 patients. (PubMed, Clin Exp Metastasis)

NF1 mutation is the strongest gene-level correlate of lung-selective metastasis in cutaneous melanoma. The NF1-mutant subtype may represent a dual-biomarker population and could warrant both pulmonary surveillance and prospective evaluation for immunotherapy.

4 days ago

Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker

BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden) • NRAS (Neuroblastoma RAS viral oncogene homolog) • NF1 (Neurofibromin 1)

TMB-H • BRAF mutation • NRAS mutation • BRAF wild-type • RAS wild-type

MSK-IMPACT

Keytruda (pembrolizumab)

Mutational Landscape and Clinical Outcomes in AML With Sole Trisomy 8. (PubMed, Hematol Oncol)

Categorizing patients on the basis of MR gene mutations revealed that the inferior survival of sole +8 patients may be attributed to the high frequency of MR gene mutations in these patients. These findings indicate the importance of genetic mutations, specifically MR genes, in sole +8 AML.

4 days ago

Clinical data • Journal

FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • STAG2 (Stromal Antigen 2)

ASXL1 mutation • TET2 mutation • SRSF2 mutation

Kinetic Signatures of RAS-BRAF Engagement Reveal Isoform Selectivity, Oncogenic Amplification, and Mutation-Dependent Inhibitor Resistance. (PubMed, bioRxiv)

We further show that inhibitor sensitivity is strongly influenced by nucleotide state and isoform-specific Switch II pocket architecture. Together, these findings establish kinetic encoding as a key determinant of RAF activation and therapeutic response in RAS-driven cancers.

5 days ago

Journal

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)

BRAF mutation

To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer (clinicaltrials.gov)

P2/3, N=574, Recruiting, SUNHO（China）BioPharmaceutical CO., Ltd. | N=90 --> 574 | Trial completion date: Jul 2028 --> Jul 2029 | Trial primary completion date: Jul 2026 --> Jul 2028

5 days ago

Enrollment change • Trial completion date • Trial primary completion date

HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)

PD-L1 expression • HER-2 positive • HER-2 expression • HER-2 underexpression • KRAS wild-type • RAS wild-type • NRAS wild-type • HER-2 positive + RAS wild-type

Herceptin (trastuzumab) • capecitabine • oxaliplatin • IAH0968

Primary large cell neuroendocrine carcinoma of pulmonary artery: a case report and literature review (PubMed, Zhonghua Jie He He Hu Xi Za Zhi)

The patient subsequently received etoposide plus cisplatin (EP), irinotecan, and third-line combination therapy of serplulimab, anlotinib, and temozolomide. Radical surgery combined with platinum-based chemotherapy constitutes the mainstay of treatment. Molecular testing can provide a basis for personalized therapy, and multiline comprehensive treatment may offer prolonged survival benefits for patients.

7 days ago

Journal

NRAS (Neuroblastoma RAS viral oncogene homolog)

NRAS mutation • NRAS exon 3 mutation

cisplatin • Focus V (anlotinib) • temozolomide • etoposide IV • irinotecan • Hetronifly (serplulimab)

Correlation between Peripheral Blood Immunological Markers and Gene Mutations in Myelodysplastic Syndrome (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)

Flow cytometry antibody indicators can suggest that MDS patients are prone to gene mutations related to chromatin regulation, transcriptional regulation, poor prognosis and leukemia transformation. The proportions of CD25+ T cells and lymphocytes were both closely related to the T-bet and GATA3 gene mutations.

8 days ago

Journal

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • JAK2 (Janus kinase 2) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • BCOR (BCL6 Corepressor) • IL2RA (Interleukin 2 receptor, alpha) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • SETBP1 (SET Binding Protein 1) • GATA2 (GATA Binding Protein 2) • PHF6 (PHD Finger Protein 6) • GATA3 (GATA binding protein 3)

TP53 mutation • KRAS mutation • NRAS mutation • ASXL1 mutation • EZH2 mutation

Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors. (PubMed, Leukemia)

Moreover, FTY720 co-treatment resensitized G12D NRAS-mutated M14(R)701 cells to gilteritinib in vivo. Co-treatment inactivated ERK, transcriptionally downregulated SPHK1, and inactivated downstream AKT, p70 S6K and BAD, with inactivation abrogated by constitutive SPHK1 expression. The clinically applicable S1PR modulators fingolimod and mocravimod resensitize NRAS-mutated FLT3-ITD AML cells to FLT3 inhibitors, supporting potential clinical efficacy.

8 days ago

Journal

FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • SPHK1 (Sphingosine Kinase 1)

NRAS mutation • FLT3-ITD mutation • FLT3 mutation • RAS mutation • NRAS Q61 • NRAS G12 • NRAS G13

Xospata (gilteritinib) • fingolimod • mocravimod (KRP-203)

Multi-mechanistic mitochondria-mediated N-methylated YKWYYRGAA-decorated nano-chitosan conjugate carrier for treatment of NRAS-mutant-harbouring lung carcinoma. (PubMed, Carbohydr Polym)

The inhaled P2-grafted nanochitosan provided a positive lung cancer recovery with reduced systemic exposure and hematological/biochemical toxicities. Single instead of dimethylation of YKWYYRGAA promoted the cascades of inter-dependent anti-cancer activities and efficacy of nanochitosan.

8 days ago

Journal

NRAS (Neuroblastoma RAS viral oncogene homolog) • CDH1 (Cadherin 1) • GSTP1 (Glutathione S-transferase pi 1) • FASLG (Fas ligand) • VIM (Vimentin) • EZR (Ezrin) • CDH2 (Cadherin 2) • MMP9 (Matrix metallopeptidase 9) • ULBP1 (UL16 Binding Protein 1)

EGFR mutation • NRAS mutation